MIRTAZAPINE tablet, film coated Estados Unidos - inglés - NLM (National Library of Medicine)

mirtazapine tablet, film coated

tya pharmaceuticals - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 15 mg - mirtazapine tablets, usp are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine in the treatment of major depressive disorder was established in 6- week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders-3rd edition (dsm-iii) category of major depressive disorder (see ). clinical pharmacology a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. the effectiveness of mirtazap

MIRTAZAPINE tablet, film coated Estados Unidos - inglés - NLM (National Library of Medicine)

mirtazapine tablet, film coated

tya pharmaceuticals - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 30 mg - mirtazapine tablets, usp are indicated for the treatment of major depressive disorder.  the efficacy of mirtazapine in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders-3rd edition (dsm-iii) category of major depressive disorder (see ).  a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation.  the effectiveness of mirtazapine in hospitalized depressed patients has not b

BICA VERA  1.5 % GLUCOSE 1.75 MMOLL CALCIUM Israel - inglés - Ministry of Health

bica vera 1.5 % glucose 1.75 mmoll calcium

fresenius medical care israel p.b., ltd. - calcium chloride dihydrate; calcium chloride dihydrate; glucose monohydrate; glucose monohydrate; magnesium chloride hexahydrate; magnesium chloride hexahydrate; sodium chloride; sodium chloride; sodium hydrogen carbonate; sodium hydrogen carbonate - solution for peritoneal dialysis - sodium chloride 11.57 g/l; calcium chloride dihydrate 0.5145 g/l; magnesium chloride hexahydrate 0.2033 g/l; sodium chloride 5.786 g/l; glucose monohydrate 33.0 g/l; glucose monohydrate 16.5 g/l; magnesium chloride hexahydrate 0.1017 g/l; calcium chloride dihydrate 0.2573 g/l; sodium hydrogen carbonate 2.940 g/l; sodium hydrogen carbonate 5.880 g/l - combinations of electrolytes - end-stage (decompensated ) chronic renal failure of any origin treated with peritoneal dialysis.17/10/2017 בקשה לשינוי משטר מינון שינוי משטר מינון בהתאם למאושר באירופה

WARFARIN SODIUM tablet Estados Unidos - inglés - NLM (National Library of Medicine)

warfarin sodium tablet

bryant ranch prepack - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 2 mg

CARDENE SR- nicardipine hydrochloride capsule, extended release Estados Unidos - inglés - NLM (National Library of Medicine)

cardene sr- nicardipine hydrochloride capsule, extended release

carilion materials management - nicardipine hydrochloride (unii: k5bc5011k3) (nicardipine - unii:cz5312222s) - nicardipine hydrochloride 30 mg - cardene sr is indicated for the treatment of hypertension. cardene sr may be used alone or in combination with other anti-hypertensive drugs. cardene is contraindicated in patients with hypersensitivity to the drug. because part of the effect of cardene is secondary to reduced afterload, the drug is also contraindicated in patients with advanced aortic stenosis. reduction of diastolic pressure by any means in these patients may worsen rather than improve myocardial oxygen balance.

RIMANTADINE HYDROCHLORIDE tablet, film coated Estados Unidos - inglés - NLM (National Library of Medicine)

rimantadine hydrochloride tablet, film coated

carilion materials management - rimantadine hydrochloride (unii: jei07oos8y) (rimantadine - unii:0t2ef4jqtu) - rimantadine hydrochloride 100 mg - rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza a virus in adults (17 years and older). rimantadine hydrochloride tablet is indicated for prophylaxis against influenza a virus in children (1 year to 16 years of age). in controlled studies of children (1 year to 16 years of age), healthy adults (17 years and older), and elderly patients (65 years of age and older), rimantadine hydrochloride has been shown to be safe and effective in preventing signs and symptoms of infection caused by various strains of influenza a virus. since rimantadine hydrochloride does not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically-related viruses. following vaccination during an influenza outbreak, rimantadine hydrochloride prophylaxis should be considered for the 2 to 4 week

VENLAFAXINE HYDROCHLORIDE capsule extended release Estados Unidos - inglés - NLM (National Library of Medicine)

venlafaxine hydrochloride capsule extended release

unit dose services - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 75 mg

GLIPIZIDE ER- glipizide tablet, film coated, extended release Estados Unidos - inglés - NLM (National Library of Medicine)

glipizide er- glipizide tablet, film coated, extended release

carilion materials management - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 10 mg - glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide extended-release tablets are contraindicated in patients with: - known hypersensitivity to glipizide or any excipients in the tablets. known hypersensitivity to glipizide or any excipients in the tablets. - type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

BISOPROLOL FUMARATE tablet Estados Unidos - inglés - NLM (National Library of Medicine)

bisoprolol fumarate tablet

carilion materials management - bisoprolol fumarate (unii: ur59kn573l) (bisoprolol - unii:y41js2nl6u) - bisoprolol fumarate 5 mg - bisoprolol fumarate is indicated in the management of hypertension. it may be used alone or in combination with other antihypertensive agents. bisoprolol fumarate is contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third degree av block, and marked sinus bradycardia.

SULFAMETHOXAZOLE AND TRIMETHOPRIM suspension Estados Unidos - inglés - NLM (National Library of Medicine)

sulfamethoxazole and trimethoprim suspension

atlantic biologicals corps - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 200 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim oral suspension and other antibacterial drugs, sulfamethoxazole and trimethoprim oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. for the treatment of urinary tract infections due to susceptible strains of the following organisms: and . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis proteus vulga